SCHEMBL20205892

SCHEMBL20205892

CCN1CCC(C)(NC(=O)c2cccc(Cl)c2C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MT-CO2 P00403 2/20 0.46
CHRM5 P08912 2/20 0.42
CHRM1 P11229 2/20 0.42
CHRM3 P20309 1/20 0.42
TAS1R3 Q7RTX0 2/20 0.42
TAS1R1 Q7RTX1 2/20 0.42
TAS1R2 Q8TE23 2/20 0.42
RET P07949 1/20 0.42
CCR3 P51677 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
THRB P10828 1/20 0.39
OPRM1 P35372 2/20 0.39
OPRD1 P41143 2/20 0.39
OPRK1 P41145 2/20 0.39
ACKR3 P25106 1/20 0.39
F9 P00740 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21652015 0.89 CHRM5 (0.53) MT-CO2CHRM5CHRM1CHRM3CCR3
SCHEMBL25503769 0.83 RET (0.44) CHRM5CHRM1CHRM3RET
SCHEMBL20206003 0.83 RET (0.48) RETP2RX7
SCHEMBL20147578 0.83 MT-CO2 (0.46) MT-CO2TAS1R3TAS1R1TAS1R2RET
SCHEMBL20147943 0.82 TAS1R3 (0.41) MT-CO2TAS1R3TAS1R1TAS1R2RET
SCHEMBL25504103 0.82 RET (0.43) MT-CO2CHRM5CHRM1CHRM3RET
SCHEMBL22857091 0.81 CHRM5 (0.48) CHRM5CHRM1CHRM3RETCCR3
SCHEMBL20158860 0.81 TAS1R3 (0.43) MT-CO2TAS1R3TAS1R1TAS1R2RET
SCHEMBL20205890 0.78 MAPT (0.47) RETCCR3MEN1KMT2ATHRB
SCHEMBL25504250 0.78 P2RX7 (0.51) RETCCR3OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 MT-CO2 4624/4885CHRM5 2607/4885CHRM1 2035/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MT-CO2 4624/4885CHRM5 2607/4885CHRM1 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.